Medi-Caps Reports FY26 Consolidated Net Loss of Rs 303.75 Lacs Amid Market Headwinds

Medi-Caps Limited has announced its audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors, meeting on May 21, 2026, approved the results along with the re-appointment of Praveen Shrivastava & Company, Chartered Accountants, as the internal auditor for the financial year 2026-27. The statutory auditors, Rawka & Associates, provided an unmodified opinion on the annual audited financial results.

Financial Performance Overview

For the financial year ended March 31, 2026, the company reported a consolidated net loss of Rs 303.75 lacs, compared to a loss of Rs 57.10 lacs in the previous year. On a standalone basis, the net loss for the year was Rs 13.87 lacs, a decline from the net profit of Rs 55.51 lacs reported in FY25. The company attributed the consolidated loss to unstable political conditions in its major market, the USA, and the standalone loss to volatile market conditions in the real estate sector.

The table below summarizes the key financial metrics for the standalone and consolidated results for the year ended March 31, 2026:

Metric:	Standalone (Rs in Lacs)	Consolidated (Rs in Lacs)
Revenue from Operations	230.59	1244.85
Net Profit/(Loss) Before Tax	(12.46)	(302.34)
Net Profit/(Loss) After Tax	(13.87)	(303.75)
Total Comprehensive Income	(63.21)	(966.49)
Equity Share Capital	1247.00	1247.00
Reserves	5424.19	9914.18
Basic EPS (Rs)	(0.11)	(2.44)
Diluted EPS (Rs)	(0.11)	(2.44)

Quarterly Performance

For the quarter ended March 31, 2026, the standalone revenue from operations stood at Rs 53.35 lacs, compared to Rs 89.08 lacs in the corresponding quarter of the previous year. The standalone net loss after tax for the quarter was Rs 31.29 lacs, against a net profit of Rs 70.61 lacs in the same quarter last year. On a consolidated basis, revenue from operations for the quarter was Rs 344.94 lacs, compared to Rs 696.35 lacs in the prior year quarter. The consolidated net profit after tax for the quarter stood at Rs 304.18 lacs, compared to Rs 171.84 lacs in the corresponding quarter of the previous year.

The table below presents the quarterly financial highlights:

Metric:	Standalone Q4 FY26 (Rs in Lacs)	Standalone Q4 FY25 (Rs in Lacs)	Consolidated Q4 FY26 (Rs in Lacs)	Consolidated Q4 FY25 (Rs in Lacs)
Revenue from Operations	53.35	89.08	344.94	696.35
Net Profit/(Loss) After Tax	(31.29)	70.61	304.18	171.84
Total Comprehensive Income	(145.67)	45.25	(485.52)	12.25
Basic EPS (Rs)	(0.25)	0.57	2.44	1.38
Diluted EPS (Rs)	(0.25)	0.57	2.44	1.38

Operational Highlights

Revenue from operations on a consolidated basis stood at Rs 1244.85 lacs for FY26, down from Rs 2547.71 lacs in the previous year. The Pharma Division reported a segment revenue of Rs 1014.26 lacs, while the Real Estate Division contributed Rs 230.59 lacs. The Pharma Division incurred a segment loss of Rs 288.58 lacs before tax and interest, whereas the Real Estate Division reported a loss of Rs 12.46 lacs for the year.

The company's total consolidated assets as of March 31, 2026, were Rs 11546.42 lacs, comprising non-current assets of Rs 6844.00 lacs and current assets of Rs 4702.42 lacs. The total equity and liabilities stood at Rs 11546.42 lacs, with equity of Rs 11161.18 lacs and liabilities of Rs 385.24 lacs. The full format of the audited financial results is available on the BSE website at www.bseindia.com and on the company's website at www.medicaps.com .

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	+7.54%	+7.08%	-9.42%	-30.07%	-33.68%

Medi caps Limited has officially declared to BSE that it does not qualify as a Large Corporate under SEBI's debt securities framework, exempting it from specific regulatory compliance requirements. The declaration was filed on April 8, 2026, addressing the non-applicability of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Regulatory Compliance Declaration

The company formally notified BSE that it does not fall under the Large Corporate category as on March 31, 2026, as per the framework provided in the SEBI circular regarding fund raising by issuance of debt securities by large entities. This declaration means that the requirement of filing disclosures in the specified format under the aforementioned circular is not applicable to Medi-Caps Limited.

Financial Position Details

As part of the mandatory disclosure format, the company provided key financial information demonstrating its non-applicability status:

Parameter	Details
Company Name	MEDI-CAPS LIMITED
CIN	L70100MP1983PLC002231
Outstanding Borrowings (as on March 31, 2026)	0.00 crore
Credit Rating Status	Not Applicable
Stock Exchange for Fine Payment	Not Applicable

The company's zero outstanding borrowings as on March 31, 2026, clearly supports its position of not qualifying as a Large Corporate under the SEBI framework.

Regulatory Framework Reference

The declaration specifically references SEBI Operational circular SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, and its update from April 13, 2022. The company confirmed that it does not meet the applicability criteria given under Chapter XII of this operational circular, which defines the parameters for Large Corporate classification.

Official Authorization

The filing was duly authorized and signed by key company officials:

Abhishek Jain - Company Secretary & Compliance Officer (M. No. A36699)
Hemant Sethi - Chief Financial Officer

Both officials digitally signed the declaration on April 8, 2026, ensuring proper corporate governance and compliance with filing requirements. The company has requested BSE to take the declaration on record, completing the necessary regulatory notification process.